About ImmunoGenesis
ImmunoGenesis is a private company based in Doylestown, Pennsylvania. It has reported $50,176,110 raised in two offerings on Form D since April 2024. Its chief executive is Jennifer Barlow.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 18, 2024 | Jan 15, 2025 | $5,749,998of $24.9M target | 2 | $2.8M | EquityRule 506(b) | Form D ↗ |
| Mar 18, 2024 | Apr 3, 2024 | $44,426,112of $66.5M target | 88 | $504K | Equity, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, two offerings | $50,176,110 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on ImmunoGenesis's Form D filed Jan 15, 2025.
MC
Michael Curran
Director
TK
Ted Koutouzis
Director
JB
Jennifer Barlow
Chief Executive Officer and director
RS
Robert Stein
Director
CS
Clifford Stocks
Director
TB
Thomas Barton
Director
Earlier filings also listed Jeremy Barton (executive officer, last listed Apr 2024), James Barlow (chief executive officer and director, last listed Apr 2024), Federica Pericle (executive officer, last listed Apr 2024) and Federica O'Brien (executive officer, last listed Apr 2024).